Daily Cosmetic Research Analysis
Three impactful studies span cosmetic dermatologic surgery outcomes, fluoride-free oral care, and regenerative aesthetics. A multicenter cohort shows sustained 1-year improvements in patient-reported satisfaction after Mohs surgery with location- and size-specific determinants, while a meta-analysis finds hydroxyapatite toothpaste comparable to fluoride for early caries control. A randomized split-face trial suggests ECM/SVF-gel may outperform a CO-based comparator for acne scars.
Summary
Three impactful studies span cosmetic dermatologic surgery outcomes, fluoride-free oral care, and regenerative aesthetics. A multicenter cohort shows sustained 1-year improvements in patient-reported satisfaction after Mohs surgery with location- and size-specific determinants, while a meta-analysis finds hydroxyapatite toothpaste comparable to fluoride for early caries control. A randomized split-face trial suggests ECM/SVF-gel may outperform a CO-based comparator for acne scars.
Research Themes
- Patient-reported outcomes and aesthetic satisfaction after dermatologic oncology surgery
- Fluoride-free hydroxyapatite toothpaste efficacy for early caries prevention and remineralization
- Regenerative aesthetics using ECM/SVF-gel for acne scar improvement
Selected Articles
1. Patient-reported quality of life and aesthetic satisfaction continues to improve for 1-year after Mohs surgery: A multicenter prospective cohort study.
In a 4-center prospective cohort (N=990), patient-reported aesthetic satisfaction and quality-of-life scores improved over one year after facial Mohs surgery. Tumor location (notably nose), defect size, sex, and prior history significantly influenced outcomes, whereas reconstruction type did not.
Impact: This large, multicenter, prospective dataset clarifies determinants of patient-reported outcomes after Mohs surgery, informing personalized counseling and expectation management.
Clinical Implications: Use tumor location and defect size to risk-stratify for psychosocial distress and lower scar satisfaction; counsel patients with nasal or periocular tumors accordingly. Reconstruction technique may be chosen for oncologic/functional reasons without compromising satisfaction.
Key Findings
- Patient-reported FACE-Q satisfaction improved across 1 year post-Mohs surgery.
- Nasal tumor location associated with lower appearance and scar satisfaction (P = .026, P < .001) and higher psychosocial distress (P = .004).
- Larger defects increased psychosocial distress (P = .037) and reduced scar appraisal (P = .008). Reconstruction type did not influence satisfaction.
Methodological Strengths
- Multicenter prospective cohort with large sample size (N=990)
- Use of a validated patient-reported outcome instrument (FACE-Q) with repeated measures
Limitations
- Observational design limits causal inference
- Potential selection and residual confounding; conducted in U.S. centers only
Future Directions: Integrate PROs into shared decision-making and develop targeted psychosocial interventions for high-risk sites (nose, periocular). Validate findings internationally and assess digital tools to monitor recovery.
BACKGROUND: Despite the growth in patient-centered care, multicenter prospective studies investigating satisfaction after skin cancer surgery are limited. OBJECTIVE: To assess trends in esthetic satisfaction, symptoms, and quality of life over 1 year in facial skin cancer patients. METHODS: Patients with facial skin cancer who underwent surgery were enrolled at 4 hospitals across the United States. A total of 990 patients were included. The FACE-Q Skin Cancer questionnaire was administered before surgery, at 2-week, 6-month, and 1-year intervals postsurgery. RESULTS: Patients reported increased satisfaction with FACE-Q scales over 1 year. Significant factors influencing outcomes included sex, age, history of facial skin cancer, cosmetic surgery, defect size, and cancer location. Males reported higher satisfaction with appearance (P = .003) and scar (P < .001), and reduced psychosocial distress (P < .001). Larger defects were associated with greater psychosocial distress (P = .037) and lower scar appraisal (P = .008). Patients with nose skin cancer reported lower satisfaction with appearance and scars (P = .026, P < .001), higher psychosocial distress (P = .004), and increased cancer worry (P = .045). Patients with cancer near the eyes reported increased cancer worry (P = .004). Reconstruction types did not influence satisfaction. CONCLUSIONS: Clinical and patient characteristics significantly influence patient-reported outcomes, highlighting the need for personalized treatment approaches to optimize outcomes in dermatologic surgery.
2. The role of hydroxyapatite-based, fluoride-free toothpastes on the prevention and the remineralization of initial caries lesions: A systematic review and meta-analysis.
This systematic review and meta-analysis of in situ RCTs found hydroxyapatite toothpaste comparable to fluoride in preventing lesion development/progression by DMFS/ICDAS, with significant benefits in lesion size and fluorescence at 6 months. Pooled RR (0.98) and OR (0.90) were non-significant, supporting HAP as a fluoride-free alternative.
Impact: Addresses growing demand for fluoride-free oral care with quantitative synthesis suggesting equivalence to fluoride for early caries control.
Clinical Implications: Hydroxyapatite toothpaste can be recommended as a fluoride-free option for patients seeking non-fluoride products, particularly for early enamel lesions, with monitoring as standard of care.
Key Findings
- No significant differences between HAP and fluoride toothpastes for lesion development/progression (DMFS/ICDAS).
- Significant improvements at 6 months in lesion size (p < 0.0001) and fluorescence values (p = 0.01) favoring HAP.
- Meta-analysis: RR 0.98 (p = 0.61; 95% CI 0.85–1.12) and OR 0.90 (p = 0.68; 95% CI 0.57–1.42) showed no significant differences.
Methodological Strengths
- Comprehensive multi-database search with PRISMA-aligned methods
- Quantitative synthesis (meta-analysis) of randomized in situ trials
Limitations
- Only four eligible studies; limited power and generalizability
- In situ RCT context and short follow-up (6 months) may not fully reflect clinical conditions
Future Directions: Conduct pragmatic, longer-term clinical RCTs across age groups to confirm equivalence and evaluate caries incidence, safety, and adherence in real-world settings.
OBJECTIVES: Τhe aim of the present systematic review and meta-analysis was to critically appraise all evidence available on the effectiveness of biomimetic hydroxyapatite (HAP) toothpastes in promoting remineralization and inhibiting demineralization. DATA: A literature search was conducted in electronic databases to identify in situ randomized controlled trials in children, adolescents, and young adults aged <25 years evaluating the effectiveness of fluoride-free HAP compared to conventional fluoride toothpastes. SOURCES: Medline (via Pubmed), Embase, Scopus, Cochrane Central Register of Controlled Trials, Dentistry & Oral Sciences Source, LILACS database were searched. Additional search of the grey literature, abstracts of conferences and meetings as well as manual search of the reference lists of retrieved studies, was also performed. STUDY SELECTION: The search retrieved 68 studies of which 4 were considered eligible. CONCLUSIONS: Development of new and progression of existing lesions, recorded using DMFS/ICDAS indices, showed no significant differences between HAP and fluoride toothpastes. Significant differences were recorded in lesion size (p < 0.0001) and fluorescence value (p = 0.01) after 6 months. Meta-analysis showed non-significant Risk Ratio (0.98, p = 0.61; 95 % CIs 0.85, 1.12) and Odds Ratio (0.90, p = 0.68; 95 % CIs 0.57, 1.42) for HAP and fluoride toothpastes. CLINICAL SIGNIFICANCE: HAP toothpaste could be an effective alternative to fluoride-containing toothpaste in preventing caries progression and promoting enamel remineralization. The comparable performance of HAP to fluoride, coupled with its superior biocompatibility and lack of toxicity, positions it as a promising option for individuals seeking fluoride-free oral care solutions.
3. Comparison of the Effects of Adipose Extracellular Matrix/Stromal Vascular Fraction Gel Injection and CO
In an assessor-blinded, randomized split-face trial (11 enrolled; 10 completed), a single ECM/SVF-gel injection achieved greater 24-week ECCA scar score reductions than a CO-based comparator on the contralateral side, with an acceptable safety profile.
Impact: Provides early randomized evidence that regenerative, autologous ECM/SVF-gel may outperform a device-based comparator for acne scars, supporting regenerative aesthetics.
Clinical Implications: ECM/SVF-gel injections may be considered for moderate-to-severe acne scars as a regenerative filler option, with split-face data suggesting superior scar score reduction at 24 weeks versus a CO-based modality.
Key Findings
- Randomized, assessor-blinded split-face design comparing ECM/SVF-gel vs a CO-based comparator.
- At 24 weeks, mean ECCA score change favored ECM/SVF-gel (-60.25) over the CO side (-43.25).
- Trial registration reported (NCT06116162); safety deemed acceptable.
Methodological Strengths
- Randomized split-face within-subject comparison with assessor blinding
- Prospective design with a prespecified clinical endpoint (ECCA) and trial registration
Limitations
- Small single-center sample (10 completers) limits generalizability and power
- Open-label to participants/providers; comparator details truncated/unclear in report
Future Directions: Larger, multicenter RCTs with standardized comparators and longer follow-up should verify efficacy, optimize dosing/technique, and evaluate durability and safety.
BACKGROUND: Adipose extracellular matrix/stromal vascular fraction gel (ECM/SVF-gel) contains adipose-derived stem cells, extracellular matrix, and other cell components, and possesses the ability to promote collagen production and serve as a filling agent. AIM: To assess the efficacy and safety of ECM/SVF-gel injection for the treatment of acne scars, compared to CO METHODS: We performed an open-label, investigator-initiated, assessor-blinded, split-face trial in Xijing Hospital, China, between July 11, 2020, and December 30, 2022. Patients exhibiting moderate to severe acne scars were randomly assigned to a single ECM/SVF-gel injection on one half of the face or two sessions of CO RESULTS: A total of 11 participants were enrolled, and 10 completed the follow-up. The mean age of patients was 27.5 ± 4.2, 7 female and four male, seven with Fitzpatrick skin Type III and four with Type IV. At 24weeks, the mean change in ECCA score was -60.25 on the side of ECM/SVF-gel injection and - 43.25 on the side of CO CONCLUSIONS: ECM/SVF-gel injection is an effective and safe approach in the treatment of acne scars. TRIAL REGISTRATION: ClinicalTrials.gov number: NCT06116162.